Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Investig Drugs. 2008 Nov;17(11):1663-70. doi: 10.1517/13543784.17.11.1663 .

Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome.

Author information

  • 1Catholic University of Leuven, University Hospital Gasthuisberg, Department of Internal Medicine, Division of Gastroenterology, Leuven, Belgium.

Abstract

Renzapride is a novel drug currently under clinical evaluation for the treatment of irritable bowel syndrome (IBS). Renzapride is a mixed 5-hydroxytryptamine type 4 (5-HT4) agonist and 5-HT3 receptor antagonist that has a stimulatory effect on gastrointestinal motility and transit, as established by in vivo and in vitro studies. Its therapeutic efficacy, tolerability and safety have been evaluated in diabetic gastroparesis in a single study, as well as in IBS in a few other studies. Phase II studies indicated potential beneficial effects on symptoms and bowel habits in patients with constipation-predominant IBS and mixed-type IBS. The outcome of Phase III studies is currently under evaluation.

PMID:
18922103
DOI:
10.1517/13543784.17.11.1663
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center